Ayala Pharmaceuticals Inc (ADXS)

[hovacre]

Some language from the PR that caught my eye, as well:

Based on discussions over the past several months with a number of experts in the field regarding our AIM2CERV trial, we have become increasingly optimistic about the prospects of this study.

You guys have pointed this out, for sure, but there's something that strikes me a bit differently. Our main expert is Brad Monk, who is a big gyn onc in the field, and he has been something of a champion over the years. Recently, however, he's been fairly quiet about his excitement for Axal, and he's expressed some uncertainty about the EMA app's success in his presentations (language like "Is this enough to get approved? I'm not sure, but it looks interesting."). Monk is a sharp dude, and I have had the privilege of working and speaking with him on a few occasions. At that time, he liked Axal, but it really seems as though ADXS has not been that good to him over the past few years.

This statement to me signals that Monk is still in the fold, and that he is making a meaningful contribution to the discussion. If ADXS has his confidence, then this may be a big reason why they're continuing AIM2CERV. If eminent leaders in the field continue to see an unmet need for Axal, even after approval of pembro, then that is a sign we should all pay attention to.